Pub Date : 2023-06-01DOI: 10.3928/00485713-20230519-01
José Diogo R. de Souza, José Alexandre S. Crippa
{"title":"The Use of Cannabinoids in Clinical Psychiatry","authors":"José Diogo R. de Souza, José Alexandre S. Crippa","doi":"10.3928/00485713-20230519-01","DOIUrl":"https://doi.org/10.3928/00485713-20230519-01","url":null,"abstract":"","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46352216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.3928/00485713-20230523-01
A. Nierenberg
{"title":"Prisons as a De Facto Mental Health System","authors":"A. Nierenberg","doi":"10.3928/00485713-20230523-01","DOIUrl":"https://doi.org/10.3928/00485713-20230523-01","url":null,"abstract":"","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41813654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.3928/00485713-20230506-01
Hülya Türkmen, Selda Yörük
This randomized controlled prospective experimental trial was conducted with 46 students with dysmenorrhea who were randomized in a 1:1 ratio to the heat treatment group (HTG) ( n = 23) and control group (CG) ( n = 23). To HTG, dry heat was applied for 20 minutes to the lower abdominal region of the subjects when their dysmenorrhea was most severe. Visual Analogue Scale (VAS), the Short Form McGill Pain Questionnaire (SF-MPQ), the Menstrual Attitude Questionnaire (MAQ), and the Depression Anxiety and Stress Scale (DASS) were used in this study. At the first menstrual cycle, both groups received the questionnaires, and no treatment was applied. At the second, third, and fourth menstrual cycles, VAS and SF-MPQ were applied before the treatment (T1), right after the treatment (T2), and 2 hours after the treatment (T3). MAQ and DASS were applied right after the treatment. Seven subjects from HTG and four subjects from CG were excluded from the study on account of their analgesic medicine usage, inability to menstruate, or by their own requests. When HTG and CG were compared, the decrease in the dysmenorrhea pain after the heat treatment in each of the three menstrual cycles was found to be statistically significant ( P < 0.05). In each of the four menstrual cycles, depression, anxiety, and stress were detected in each subject in both groups. However, the effectiveness of the treatment was not determined ( P > 0.05). In HTG, awareness of the changes during menstruation was diminished with time. [ Psychiatr Ann . 2023;53(6):270–281.]
{"title":"Effects of Heat Treatment On Dysmenorrhea and Its Mental Health Outcomes: A Randomized Clinical Trial","authors":"Hülya Türkmen, Selda Yörük","doi":"10.3928/00485713-20230506-01","DOIUrl":"https://doi.org/10.3928/00485713-20230506-01","url":null,"abstract":"This randomized controlled prospective experimental trial was conducted with 46 students with dysmenorrhea who were randomized in a 1:1 ratio to the heat treatment group (HTG) (\u0000 n\u0000 = 23) and control group (CG) (\u0000 n\u0000 = 23). To HTG, dry heat was applied for 20 minutes to the lower abdominal region of the subjects when their dysmenorrhea was most severe. Visual Analogue Scale (VAS), the Short Form McGill Pain Questionnaire (SF-MPQ), the Menstrual Attitude Questionnaire (MAQ), and the Depression Anxiety and Stress Scale (DASS) were used in this study. At the first menstrual cycle, both groups received the questionnaires, and no treatment was applied. At the second, third, and fourth menstrual cycles, VAS and SF-MPQ were applied before the treatment (T1), right after the treatment (T2), and 2 hours after the treatment (T3). MAQ and DASS were applied right after the treatment. Seven subjects from HTG and four subjects from CG were excluded from the study on account of their analgesic medicine usage, inability to menstruate, or by their own requests. When HTG and CG were compared, the decrease in the dysmenorrhea pain after the heat treatment in each of the three menstrual cycles was found to be statistically significant (\u0000 P\u0000 < 0.05). In each of the four menstrual cycles, depression, anxiety, and stress were detected in each subject in both groups. However, the effectiveness of the treatment was not determined (\u0000 P\u0000 > 0.05). In HTG, awareness of the changes during menstruation was diminished with time.\u0000 \u0000 [\u0000 Psychiatr Ann\u0000 . 2023;53(6):270–281.]","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41716398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.3928/00485713-20230515-02
G. Rossi, J. C. A. Reis, J. Hallak, R. G. Santos
This article will summarize the current knowledge and scientific evidence regarding cannabidiol as a possible pharmacological tool for anxiety disorders. Although the use of this substance in medical practice is gaining momentum, gaps can still be found in the current knowledge regarding its molecular targets, drug-to-drug interactions, efficacy in different populations, adequate dosage, duration of treatment, and correct formulation. Moreover, current evidence is still preliminary, lacking robust, blinded, and placebo-controlled clinical trials in many areas of investigation. After reading this article, readers should have a thorough understanding of the current scientific evidence regarding the use of CBD as an anxiolytic drug. [ Psychiatr Ann . 2023;53(6):242–246.]
{"title":"Current Evidence of Cannabidiol's Potential as an Anxiolytic Agent","authors":"G. Rossi, J. C. A. Reis, J. Hallak, R. G. Santos","doi":"10.3928/00485713-20230515-02","DOIUrl":"https://doi.org/10.3928/00485713-20230515-02","url":null,"abstract":"\u0000 This article will summarize the current knowledge and scientific evidence regarding cannabidiol as a possible pharmacological tool for anxiety disorders. Although the use of this substance in medical practice is gaining momentum, gaps can still be found in the current knowledge regarding its molecular targets, drug-to-drug interactions, efficacy in different populations, adequate dosage, duration of treatment, and correct formulation. Moreover, current evidence is still preliminary, lacking robust, blinded, and placebo-controlled clinical trials in many areas of investigation. After reading this article, readers should have a thorough understanding of the current scientific evidence regarding the use of CBD as an anxiolytic drug.\u0000 \u0000 [\u0000 Psychiatr Ann\u0000 . 2023;53(6):242–246.]\u0000 \u0000","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46180766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.3928/00485713-20230421-01
P. Jaini, Jamie K. Alexander, Sara Elchehabi, J. Briggs, Dustin S DeMoss, Cheryl L Hurd, A. J. Rush
Scurvy is often considered to be a historical disease that once affected sailors, and so its modern-day prevalence is underestimated. Scurvy can present in various ways, such as with mucocutaneous and/or hematological symptoms in classic scurvy or with isolated psychiatric symptoms in neuropsychiatric scurvy. We describe two patient presentations of scurvy with borderline-low vitamin C levels and neuropsychiatric symptoms. Patient 1 presented with an exacerbation of major depressive symptoms and classic physical symptoms of scurvy, while Patient 2 presented with new-onset psychotic symptoms and no physical symptoms. Both patients had significant improvement of symptoms with vitamin C supplementation. We also conducted a literature search of MED-LINE via PubMed, identifying 16 cases of patients who met criteria for a scurvy diagnosis and presented with psychiatric symptoms that responded to vitamin C supplementation. The cases and literature review revealed that patients with scurvy can have variable psychiatric symptoms with or without the presence of mucocutaneous signs. Therefore, to optimize detection of suspected cases, diagnostic guidelines for scurvy should include psychiatric symptoms in addition to classic signs. Patients with acute psychiatric symptoms and a history of malnutrition should be screened for hypovitaminosis C. An empirical trial of vitamin C supplementation may also be of value in some cases when borderline-low vitamin C levels are found in suspected neuropsychiatric scurvy. [ Psychiatr Ann . 2023;53(6):282–288.]
{"title":"Psychiatric Manifestations of Modern Scurvy: A Case Series and Literature Review","authors":"P. Jaini, Jamie K. Alexander, Sara Elchehabi, J. Briggs, Dustin S DeMoss, Cheryl L Hurd, A. J. Rush","doi":"10.3928/00485713-20230421-01","DOIUrl":"https://doi.org/10.3928/00485713-20230421-01","url":null,"abstract":"\u0000 Scurvy is often considered to be a historical disease that once affected sailors, and so its modern-day prevalence is underestimated. Scurvy can present in various ways, such as with mucocutaneous and/or hematological symptoms in classic scurvy or with isolated psychiatric symptoms in neuropsychiatric scurvy. We describe two patient presentations of scurvy with borderline-low vitamin C levels and neuropsychiatric symptoms. Patient 1 presented with an exacerbation of major depressive symptoms and classic physical symptoms of scurvy, while Patient 2 presented with new-onset psychotic symptoms and no physical symptoms. Both patients had significant improvement of symptoms with vitamin C supplementation. We also conducted a literature search of MED-LINE via PubMed, identifying 16 cases of patients who met criteria for a scurvy diagnosis and presented with psychiatric symptoms that responded to vitamin C supplementation. The cases and literature review revealed that patients with scurvy can have variable psychiatric symptoms with or without the presence of mucocutaneous signs. Therefore, to optimize detection of suspected cases, diagnostic guidelines for scurvy should include psychiatric symptoms in addition to classic signs. Patients with acute psychiatric symptoms and a history of malnutrition should be screened for hypovitaminosis C. An empirical trial of vitamin C supplementation may also be of value in some cases when borderline-low vitamin C levels are found in suspected neuropsychiatric scurvy.\u0000 \u0000 [\u0000 Psychiatr Ann\u0000 . 2023;53(6):282–288.]\u0000 \u0000","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47182383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.3928/00485713-20230515-01
João F. Pedrazzi, Lucas Hassib, F. R. Ferreira
Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders whose symptoms include impaired communication and social interaction, stereotypies, and varying levels of intellectual disability. Together with these symptoms are co-occurring psychiatric or neurological conditions, often with hyperactivity and attention disorders, anxiety, depression, and epilepsy. So far, no effective treatment for ASD is available, possibly because its neurobiological basis and heterogeneous nature are not clearly understood. Clinical and preclinical trials support the involvement of the endocannabinoid system in the patho-physiology of ASD. Cannabidiol (CBD), the main nonpsychotomimetic compound of the cannabis plant, interacts with the endocannabinoid system and has significant therapeutic potential in treating several psychiatric disorders and manifestations of ASD. After this article, readers are expected to have a broad understanding of current scientific evidence and perspectives on the use of CBD in cases of ASD. [ Psychiatr Ann . 2023;53(6):247–251.]
{"title":"Therapeutic Profile of Cannabidiol in the Broad Symptomatology of Autism Spectrum Disorder: Evidence From Basic Science to Clinical Approaches","authors":"João F. Pedrazzi, Lucas Hassib, F. R. Ferreira","doi":"10.3928/00485713-20230515-01","DOIUrl":"https://doi.org/10.3928/00485713-20230515-01","url":null,"abstract":"\u0000 Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders whose symptoms include impaired communication and social interaction, stereotypies, and varying levels of intellectual disability. Together with these symptoms are co-occurring psychiatric or neurological conditions, often with hyperactivity and attention disorders, anxiety, depression, and epilepsy. So far, no effective treatment for ASD is available, possibly because its neurobiological basis and heterogeneous nature are not clearly understood. Clinical and preclinical trials support the involvement of the endocannabinoid system in the patho-physiology of ASD. Cannabidiol (CBD), the main nonpsychotomimetic compound of the cannabis plant, interacts with the endocannabinoid system and has significant therapeutic potential in treating several psychiatric disorders and manifestations of ASD. After this article, readers are expected to have a broad understanding of current scientific evidence and perspectives on the use of CBD in cases of ASD.\u0000 \u0000 [\u0000 Psychiatr Ann\u0000 . 2023;53(6):247–251.]\u0000 \u0000","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49281319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.3928/00485713-20230505-01
João Roberto F. Lisboa, João Luís Simei, José Diogo R. de Souza, Felipe V. Gomes
Schizophrenia is a complex neuropsychiatric disorder that has undergone significant advancements in its treatment. However, there are still many aspects of symptom management and prevention that could benefit from new developments in psychopharmacology. One potential avenue is the use of cannabidiol (CBD), a major phytocannabinoid found in the cannabis plant. Preliminary evidence suggests that CBD could effectively treat certain symptoms of the disorder with fewer side effects than conventional antipsychotics. This article provides the reader with an in-depth discussion of the current scientific evidence concerning the use of CBD in the treatment of schizophrenia. [ Psychiatr Ann . 2023;53(6):252–255.]
{"title":"Cannabidiol as a Treatment for Schizophrenia","authors":"João Roberto F. Lisboa, João Luís Simei, José Diogo R. de Souza, Felipe V. Gomes","doi":"10.3928/00485713-20230505-01","DOIUrl":"https://doi.org/10.3928/00485713-20230505-01","url":null,"abstract":"Schizophrenia is a complex neuropsychiatric disorder that has undergone significant advancements in its treatment. However, there are still many aspects of symptom management and prevention that could benefit from new developments in psychopharmacology. One potential avenue is the use of cannabidiol (CBD), a major phytocannabinoid found in the cannabis plant. Preliminary evidence suggests that CBD could effectively treat certain symptoms of the disorder with fewer side effects than conventional antipsychotics. This article provides the reader with an in-depth discussion of the current scientific evidence concerning the use of CBD in the treatment of schizophrenia. [ Psychiatr Ann . 2023;53(6):252–255.]","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134904403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-01DOI: 10.3928/00485713-20230417-01
Zachary B. Millman, M. Weintraub
Early intervention in psychosis can provide significant clinical benefits for patients, but disambiguating risk states from a full-threshold illness—a prerequisite for informed clinical decision-making—can be challenging. This article overviews the assessment, phenomenology, and treatment of clinical high-risk (CHR) syndromes, a set of risk factors and symptoms that indicate substantially elevated risk for psychosis when presenting among help-seeking youth. Symptoms associated with CHR states often present as qualitatively similar to those of formal psychotic disorders and may be associated with distress and behavior change. However, insight has not been lost and behavior is not seriously disorganized or dangerous. The emerging nature of these symptoms in conjunction with the young age of patients at CHR and high levels of public stigma bring unique challenges to assessment, clinical feedback, and treatment. Nonetheless, there are numerous guidelines and standards that can support clinicians in providing high quality care for this important population. [ Psychiatr Ann . 2023;53(5):194–198.]
{"title":"An Overview of Diagnostic and Clinical Considerations Pertaining to Psychosis-Risk Syndromes","authors":"Zachary B. Millman, M. Weintraub","doi":"10.3928/00485713-20230417-01","DOIUrl":"https://doi.org/10.3928/00485713-20230417-01","url":null,"abstract":"\u0000 Early intervention in psychosis can provide significant clinical benefits for patients, but disambiguating risk states from a full-threshold illness—a prerequisite for informed clinical decision-making—can be challenging. This article overviews the assessment, phenomenology, and treatment of clinical high-risk (CHR) syndromes, a set of risk factors and symptoms that indicate substantially elevated risk for psychosis when presenting among help-seeking youth. Symptoms associated with CHR states often present as qualitatively similar to those of formal psychotic disorders and may be associated with distress and behavior change. However, insight has not been lost and behavior is not seriously disorganized or dangerous. The emerging nature of these symptoms in conjunction with the young age of patients at CHR and high levels of public stigma bring unique challenges to assessment, clinical feedback, and treatment. Nonetheless, there are numerous guidelines and standards that can support clinicians in providing high quality care for this important population.\u0000 \u0000 [\u0000 Psychiatr Ann\u0000 . 2023;53(5):194–198.]\u0000 \u0000","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43351465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-01DOI: 10.3928/00485713-20230414-01
Tamara Welikson, P. E. Guvenek-Cokol
Early identification of symptoms and accurate diagnoses are necessary for referrals to intervention programs, diagnostic conceptualization, treatment planning, recovery, pharmacotherapy decision-making, improvement in prognosis, functional capacity, and possible prevention of the emergence of full diagnostic disorders. Different symptom profiles have been shown to have more efficacious treatment approaches than others; however, differential diagnoses can be complicated when psychosis-like symptoms first start to emerge. Thus, learning how to differentiate between clinical high risk for psychosis, borderline personality disorder, and posttraumatic stress disorder to determine if a singular diagnosis or multiple comorbid diagnoses are necessary to improve patient care and treatment outcomes. [ Psychiatr Ann . 2023;53(5):204–208.]
{"title":"Differential Diagnosis of Trauma Spectrum Disorders and Clinical High Risk for Psychosis","authors":"Tamara Welikson, P. E. Guvenek-Cokol","doi":"10.3928/00485713-20230414-01","DOIUrl":"https://doi.org/10.3928/00485713-20230414-01","url":null,"abstract":"\u0000 Early identification of symptoms and accurate diagnoses are necessary for referrals to intervention programs, diagnostic conceptualization, treatment planning, recovery, pharmacotherapy decision-making, improvement in prognosis, functional capacity, and possible prevention of the emergence of full diagnostic disorders. Different symptom profiles have been shown to have more efficacious treatment approaches than others; however, differential diagnoses can be complicated when psychosis-like symptoms first start to emerge. Thus, learning how to differentiate between clinical high risk for psychosis, borderline personality disorder, and posttraumatic stress disorder to determine if a singular diagnosis or multiple comorbid diagnoses are necessary to improve patient care and treatment outcomes.\u0000 \u0000 [\u0000 Psychiatr Ann\u0000 . 2023;53(5):204–208.]\u0000 \u0000","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45338942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-01DOI: 10.3928/00485713-20230424-01
Hyun Jung Kim, E. Carol
Autism spectrum disorder (ASD) and schizophrenia spectrum disorders (SSD) are currently conceptualized as distinct illnesses. However, there has been considerable debate over the association between these two disorders. Research findings over the last decade suggest a number of overlapping domains between ASD and SSD: shared environmental risk factors, genetics, neurobiological features, brain imaging, clinical features, and comorbidities. These commonalities lead to significant challenges in differentiating between the core symptoms of ASD and SSD. Misinterpretation of symptoms is common in clinical practice, particularly while working with young people at the early stage of these neurodevelopmental conditions, such as first-episode psychosis or clinical high risk. It is essential for mental health professionals to know about research-informed clinical guidelines on how to differentiate ASD and SSD in the clinical setting. [ Psychiatr Ann . 2023;53(5):209–215.]
{"title":"Autism Spectrum Disorder and Schizophrenia Spectrum Disorders","authors":"Hyun Jung Kim, E. Carol","doi":"10.3928/00485713-20230424-01","DOIUrl":"https://doi.org/10.3928/00485713-20230424-01","url":null,"abstract":"Autism spectrum disorder (ASD) and schizophrenia spectrum disorders (SSD) are currently conceptualized as distinct illnesses. However, there has been considerable debate over the association between these two disorders. Research findings over the last decade suggest a number of overlapping domains between ASD and SSD: shared environmental risk factors, genetics, neurobiological features, brain imaging, clinical features, and comorbidities. These commonalities lead to significant challenges in differentiating between the core symptoms of ASD and SSD. Misinterpretation of symptoms is common in clinical practice, particularly while working with young people at the early stage of these neurodevelopmental conditions, such as first-episode psychosis or clinical high risk. It is essential for mental health professionals to know about research-informed clinical guidelines on how to differentiate ASD and SSD in the clinical setting.\u0000 \u0000 [\u0000 Psychiatr Ann\u0000 . 2023;53(5):209–215.]","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46295870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：